Columbia University Irving Medical Center (CUIMC) led a study on the antibody-based treatment solanezumab as a treatment for Alzheimer’s disease.
Solanezumad was manufactured to reduce the level of soluble amyloid molecules, which causes the disease.
More than 2,000 patients with mild dementia participated in the multicenter trial. The primary measure of outcome is measured by a cognitive test called the Alzheimer’s Disease Assessment scale, which researchers observed did not results in any significant benefit compared with the placebo.
The authors of the study opine that its ineffectivity could be due to the fact that not enough amount of the drug was administered, or the drug should have been administered in the early stages of the disease.
A neurology professor from the CUIMC states that newer ongoing studies could lead to an effective treatment in slowing down Alzheimer’s.